Labetalol Hydrochloride

×

Overview

What is Labetalol Hydrochloride?

Labetalol HCl is an adrenergic receptor blocking agent that has both selective alpha- and nonselective beta-adrenergic receptor blocking actions in a single substance.

Labetalol HCl is a racemate, chemically designated as 5-[1-hydroxy-2-[(1-methyl-3-phenylpropyl) amino] ethyl] salicylamide monohydrochloride, and has the following structure:

Labetalol HCl has the molecular formula CHNO•HCl and a molecular weight of 364.87. It has two asymmetric centers and therefore exists as a molecular complex of two diastereoisomeric pairs. Dilevalol, the R,R' stereoisomer, makes up 25% of racemic labetalol.

Labetalol HCl is a white or off-white crystalline powder, soluble in water.

Each tablet, for oral administration contains 100 mg, 200 mg, or 300 mg of labetalol HCl.

In addition, each 100 mg tablet has the following inactive ingredients: anhydrous lactose, carnauba wax, pregelatinized starch (corn), hydroxypropyl methylcellulose, magnesium stearate, polyethylene glycol, polysorbate 80, synthetic yellow iron oxide, synthetic red iron oxide, titanium dioxide.

In addition, each 200 mg tablet has the following inactive ingredients: anhydrous lactose, carnauba wax, pregelatinized starch (corn), hydroxypropyl methylcellulose, magnesium stearate, polyethylene glycol, polydextrose, titanium dioxide, triacetin.

In addition, each 300 mg tablet has the following inactive ingredients: anhydrous lactose, carnauba wax, pregelatinized starch (corn), hydroxypropyl methylcellulose, magnesium stearate, polyethylene glycol, polysorbate 80, titanium dioxide, FD&C Blue #2 aluminum lake.

What does Labetalol Hydrochloride look like?

What are the available doses of Labetalol Hydrochloride?

Sorry No records found.

What should I talk to my health care provider before I take Labetalol Hydrochloride?

Sorry No records found

How should I use Labetalol Hydrochloride?

Labetalol hydrochloride tablets are indicated in the management of hypertension. Labetalol tablets may be used alone or in combination with other antihypertensive agents, especially thiazide and loop diuretics.

DOSAGE MUST BE INDIVIDUALIZED. The recommended dose is 100 mg daily whether used alone or added to a diuretic regimen. After 2 or 3 days, using standing blood pressure as an indicator, dosage may be titrated in increments of 100 mg b.i.d. every 2 or 3 days. The usual dosage of labetalol HCl is between 200 and 400 mg daily.

Since the full antihypertensive effect of labetalol is usually seen within the first 1 to 3 hours of the initial dose or dose increment, the assurance of a lack of an exaggerated hypotensive response can be clinically established in the office setting. The antihypertensive effects of continued dosing can be measured at subsequent visits, approximately 12 hours after a dose, to determine whether further titration is necessary.

Patients with severe hypertension may require from 1200 mg to 2400 mg per day, with or without thiazide diuretics. Should side effects (principally nausea or dizziness) occur with these doses administered b.i.d., the same total daily dose administered t.i.d. may improve tolerability and facilitate further titration. Titration increments should not exceed 200 mg b.i.d.

When a diuretic is added, an additive antihypertensive effect can be expected. In some cases this may necessitate a labetalol dosage adjustment. As with most antihypertensive drugs, optimal dosages of labetalol tablets are usually lower in patients also receiving a diuretic.

When transferring patients from other antihypertensive drugs, labetalol tablets should be introduced as recommended and the dosage of the existing therapy progressively decreased.

What interacts with Labetalol Hydrochloride?

Labetalol tablets are contraindicated in bronchial asthma, overt cardiac failure, greater than first degree heart block, cardiogenic shock, severe bradycardia, other conditions associated with severe and prolonged hypotension, and in patients with a history of hypersensitivity to any component of the product (see ).

Beta-blockers, even those with apparent cardioselectivity, should not be used in patients with a history of obstructive airway disease, including asthma.

What are the warnings of Labetalol Hydrochloride?

Hepatic Injury

Severe hepatocellular injury, confirmed by rechallenge in at least one case, occurs rarely with labetalol therapy. The hepatic injury is usually reversible, but hepatic necrosis and death have been reported. Injury has occurred after both short- and long-term treatment and may be slowly progressive despite minimal symptomatology. Similar hepatic events have been reported with a related compound, dilevalol, including two deaths. Dilevalol is one of the four isomers of labetalol. Thus, for patients taking labetalol, periodic determination of suitable hepatic laboratory tests would be appropriate. Laboratory testing should also be done at the very first symptom or sign of liver dysfunction (e.g., pruritus, dark urine, persistent anorexia, jaundice, right upper quadrant tenderness, or unexplained "flu-like" symptoms). If the patient has jaundice or laboratory evidence of liver injury, labetalol should be stopped and not restarted.

Cardiac Failure

Sympathetic stimulation is a vital component supporting circulatory function in congestive heart failure. Beta blockade carries a potential hazard of further depressing myocardial contractility and precipitating more severe failure. Although beta-blockers should be avoided in overt congestive heart failure, if necessary, labetalol can be used with caution in patients with a history of heart failure who are well-compensated. Congestive heart failure has been observed in patients receiving labetalol. Labetalol does not abolish the inotropic action of digitalis on heart muscle.

In Patients Without a History of Cardiac Failure

In patients with latent cardiac insufficiency, continued depression of the myocardium with beta-blocking agents over a period of time can, in some cases, lead to cardiac failure. At the first sign or symptom of impending cardiac failure, patients should be fully digitalized and/or be given a diuretic, and the response observed closely. If cardiac failure continues, despite adequate digitalization and diuretic, labetalol therapy should be withdrawn (gradually if possible).

Exacerbation of Ischemic Heart Disease Following Abrupt Withdrawal

Angina pectoris has not been reported upon labetalol discontinuation. However, hypersensitivity to catecholamines has been observed in patients withdrawn from beta-blocker therapy; exacerbation of angina and, in some cases, myocardial infarction have occurred after discontinuation of such therapy. When discontinuing chronically administered labetalol, particularly in patients with ischemic heart disease, the dosage should be gradually reduced over a period of 1 to 2 weeks and the patient should be carefully monitored. If angina markedly worsens or acute coronary insufficiency develops, labetalol administration should be reinstituted promptly, at least temporarily, and other measures appropriate for the management of unstable angina should be taken. Patients should be warned against interruption or discontinuation of therapy without the physician's advice. Because coronary artery disease is common and may be unrecognized, it may be prudent not to discontinue labetalol therapy abruptly even in patients treated only for hypertension.

Nonallergic bronchospasm (e.g., chronic bronchitis and emphysema) patients with bronchospastic disease should, in general, not receive beta-blockers.

Pheochromocytoma

Labetalol has been shown to be effective in lowering the blood pressure and relieving symptoms in patients with pheochromocytoma. However, paradoxical hypertensive responses have been reported in a few patients with this tumor; therefore, use caution when administering labetalol to patients with pheochromocytoma.

Diabetes Mellitus and Hypoglycemia

Beta-adrenergic blockade may prevent the appearance of premonitory signs and symptoms (e.g., tachycardia) of acute hypoglycemia. This is especially important with labile diabetics. Beta-blockade also reduces the release of insulin in response to hyperglycemia; it may therefore be necessary to adjust the dose of antidiabetic drugs.

Major Surgery

The necessity or desirability of withdrawing beta-blocking therapy prior to major surgery is controversial. Protracted severe hypotension and difficulty in restarting or maintaining a heartbeat have been reported with beta-blockers. The effect of labetalol's alpha-adrenergic activity has not been evaluated in this setting.

A synergism between labetalol and halothane anesthesia has been shown (see ).

What are the precautions of Labetalol Hydrochloride?

General

Labetalol should be used with caution in patients with impaired hepatic function since metabolism of the drug may be diminished.

(see ).

Information for Patients

As with all drugs with beta-blocking activity, certain advice to patients being treated with labetalol is warranted. This information is intended to aid in the safe and effective use of this medication. It is not a disclosure of all possible adverse or intended effects. While no incident of the abrupt withdrawal phenomenon (exacerbation of angina pectoris) has been reported with labetalol, dosing with labetalol tablets should not be interrupted or discontinued without a physician's advice. Patients being treated with labetalol tablets should consult a physician at any signs or symptoms of impending cardiac failure or hepatic dysfunction (see ). Also, transient scalp tingling may occur, usually when treatment with labetalol tablets is initiated (see ).

Laboratory Tests

As with any new drug given over prolonged periods, laboratory parameters should be observed over regular intervals. In patients with concomitant illnesses, such as impaired renal function, appropriate tests should be done to monitor these conditions.

Drug Interactions

In one survey, 2.3% of patients taking labetalol in combination with tricyclic antidepressants experienced tremor as compared to 0.7% reported to occur with labetalol alone. The contribution of each of the treatments to this adverse reaction is unknown but the possibility of a drug interaction cannot be excluded.

Drugs possessing beta-blocking properties can blunt the bronchodilator effect of beta-receptor agonist drugs in patients with bronchospasm; therefore, doses greater than the normal anti-asthmatic dose of beta-agonist bronchodilator drugs may be required.

Cimetidine has been shown to increase the bioavailability of labetalol. Since this could be explained either by enhanced absorption or by an alteration of hepatic metabolism of labetalol, special care should be used in establishing the dose required for blood pressure control in such patients.

Synergism has been shown between halothane anesthesia and intravenously administered labetalol. During controlled hypotensive anesthesia using labetalol in association with halothane, high concentrations (3% or above) of halothane should not be used because the degree of hypotension will be increased and because of the possibility of a large reduction in cardiac output and an increase in central venous pressure. The anesthesiologist should be informed when a patient is receiving labetalol.

Labetalol blunts the reflex tachycardia produced by nitroglycerin without preventing its hypotensive effect. If labetalol is used with nitroglycerin in patients with angina pectoris, additional antihypertensive effects may occur.

Care should be taken if labetalol is used concomitantly with calcium channel antagonists of the verapamil type.

While taking beta-blockers, patients with a history of severe anaphylactic reaction to a variety of allergens may be more reactive to repeated challenge, either accidental, diagnostic, or therapeutic. Such patients may be unresponsive to the usual doses of epinephrine used to treat allergic reaction.

Drug/Laboratory Test Interactions

The presence of labetalol metabolites in the urine may result in falsely elevated levels of urinary catecholamines, metanephrine, normetanephrine, and vanillylmandelic acid (VMA) when measured by fluorimetric or photometric methods. In screening patients suspected of having a pheochromocytoma and being treated with labetalol, a specific method, such as a high performance liquid chromatographic assay with solid phase extraction (e.g., 385:241,1987) should be employed in determining levels of catecholamines.

Labetalol has also been reported to produce a false-positive test for amphetamine when screening urine for the presence of drugs using the commercially available assay methods Toxi-Lab A (thin-layer chromatographic assay) and Emit-d.a.u. (radioenzymatic assay). When patients being treated with labetalol have a positive urine test for amphetamine using these techniques, confirmation should be made by using more specific methods, such as a gas chromatographic-mass spectrometer technique.

Carcinogenesis, Mutagenesis, Impairment of Fertility

Long-term oral dosing studies with labetalol for 18 months in mice and for 2 years in rats showed no evidence of carcinogenesis. Studies with labetalol, using dominant lethal assays in rats and mice, and exposing microorganisms according to modified Ames tests, showed no evidence of mutagenesis.

Pregnancy

Hypotension, bradycardia, hypoglycemia, and respiratory depression have been reported in infants of mothers who were treated with labetalol for hypertension during pregnancy. Oral administration of labetalol to rats during late gestation through weaning at doses of 2 to 4 times the MRHD caused a decrease in neonatal survival.

Labor and Delivery

Labetalol given to pregnant women with hypertension did not appear to affect the usual course of labor and delivery.

Nursing Mothers

Small amounts of labetalol (approximately 0.004% of the maternal dose) are excreted in human milk. Caution should be exercised when labetalol tablets are administered to a nursing woman.

Pediatric Use

Safety and effectiveness in pediatric patients have not been established.

Elderly Patients

As in the general population, some elderly patients (60 years of age and older) have experienced orthostatic hypotension, dizziness, or lightheadedness during treatment with labetalol. Because elderly patients are generally more likely than younger patients to experience orthostatic symptoms, they should be cautioned about the possibility of such effects during treatment with labetalol.

What are the side effects of Labetalol Hydrochloride?

Most adverse effects are mild, transient and occur early in the course of treatment. In controlled clinical trials of 3 to 4 months duration, discontinuation of labetalol tablets due to one or more adverse effects was required in 7% of all patients. In these same trials, beta-blocker control agents led to discontinuation in 8% to 10% of patients, and a centrally acting alpha-agonist in 30% of patients.

The incidence rates of adverse reactions listed in the following table were derived from multicenter controlled clinical trials, comparing labetalol, placebo, metoprolol, and propranolol, over treatment periods of 3 and 4 months. Where the frequency of adverse effects for labetalol and placebo is similar, causal relationship is uncertain. The rates are based on adverse reactions considered probably drug related by the investigator. If all reports are considered, the rates are somewhat higher (e.g., dizziness 20%, nausea 14%, fatigue 11%), but the overall conclusions are unchanged.

The adverse effects were reported spontaneously and are representative of the incidence of adverse effects that may be observed in a properly selected hypertensive patient population, i.e., a group excluding patients with bronchospastic disease, overt congestive heart failure, or other contraindications to beta-blocker therapy.

Clinical trials also included studies utilizing daily doses up to 2400 mg in more severely hypertensive patients. Certain of the side effects increased with increasing dose as shown in the table below which depicts the entire U.S. therapeutic trials data base for adverse reactions that are clearly or possibly drug related.

In addition, a number of other less common adverse events have been reported:

Body As A Whole:

Cardiovascular:

Central and Peripheral Nervous Systems:

Collagen Disorders:

Eyes:

Immunological System:

Liver and Biliary System:

Musculoskeletal System:

Respiratory System:

Skin and Appendages:

Urinary System:

Hypersensitivity:

Following approval for marketing in the United Kingdom, a monitored release survey involving approximately 6,800 patients was conducted for further safety and efficacy evaluation of this product. Results of this survey indicate that the type, severity, and incidence of adverse effects were comparable to those cited above.

Labetalol(N=227)%	Placebo(N=98)%	Propranolol(N=84)%	Metoprolol(N=49)%
fatigue	5	0	12	12
asthenia	1	1	1	0
headache	2	1	1	2
nausea	6	1	1	2
vomiting	<1	0	0	0
dyspepsia	3	1	1	0
abdominal pain	0	0	1	2
diarrhea	<1	0	2	0
taste distortion	1	0	0	0
dizziness	11	3	4	4
paresthesias	<1	0	0	0
drowsiness	<1	2	2	2
nasal stuffiness	3	0	0	0
ejaculation failure	2	0	0	0
impotence	1	0	1	3
increased sweating	<1	0	0	0
edema	1	0	0	0
postural hypotension	1	0	0	0
bradycardia	0	0	5	12
dyspnea	2	0	1	2
Skin rash	1	0	0	0
vision abnormality	1	0	0	0
vertigo	2	1	0	0
Labetalol HClDaily Dose (mg)	200	300	400	600	800	900	1200	1600	2400
Number ofPatients	522	181	606	608	503	117	411	242	175
Dizziness (%)	2	3	3	3	5	1	9	13	16
Fatigue	2	1	4	4	5	3	7	6	10
Nausea	<1	0	1	2	4	0	7	11	19
Vomiting	0	0	<1	<1	<1	0	1	2	3
Dyspepsia	1	0	2	1	1	0	2	2	4
Paresthesias	2	0	2	2	1	1	2	5	5
Nasal Stuffiness	1	1	2	2	2	2	4	5	6
Ejaculation Failure	0	2	1	2	3	0	4	3	5
Impotence	1	1	1	1	2	4	3	4	3
Edema	1	0	1	1	1	0	1	2	2

Potential Adverse Effects

In addition, other adverse effects not listed above have been reported with other beta-adrenergic blocking agents.

Central Nervous System:

Cardiovascular:

Allergic:

Hematologic:

Gastrointestinal:

The oculomucocutaneous syndrome associated with the beta-blocker practolol has not been reported with labetalol.

Clinical Laboratory Tests

There have been reversible increases of serum transaminases in 4% of patients treated with labetalol and tested, and more rarely, reversible increases in blood urea.

What should I look out for while using Labetalol Hydrochloride?

Labetalol tablets are contraindicated in bronchial asthma, overt cardiac failure, greater than first degree heart block, cardiogenic shock, severe bradycardia, other conditions associated with severe and prolonged hypotension, and in patients with a history of hypersensitivity to any component of the product (see ).

Beta-blockers, even those with apparent cardioselectivity, should not be used in patients with a history of obstructive airway disease, including asthma.

What might happen if I take too much Labetalol Hydrochloride?

Overdosage with labetalol causes excessive hypotension that is posture sensitive, and sometimes, excessive bradycardia. Patients should be placed supine and their legs raised if necessary to improve the blood supply to the brain. If overdosage with labetalol follows oral ingestion, gastric lavage or pharmacologically induced emesis (using syrup of ipecac) may be useful for removal of the drug shortly after ingestion. The following additional measures should be employed if necessary: - administer atropine or epinephrine. - administer a digitalis glycoside and a diuretic. Dopamine or dobutamine may also be useful. - administer vasopressors, e.g., norepinephrine. There is pharmacological evidence that norepinephrine may be the drug of choice. - administer epinephrine and/or an aerosolized beta-agonist. - administer diazepam.

In severe beta-blocker overdose resulting in hypotension and/or bradycardia, glucagon has been shown to be effective when administered in large doses (5 to 10 mg rapidly over 30 seconds, followed by continuous infusion of 5mg/hr that can be reduced as the patient improves).

Neither hemodialysis nor peritoneal dialysis removes a significant amount of labetalol from the general circulation (<1%).

The oral LD value of labetalol HCl in the mouse is approximately 600 mg/kg and in the rat is greater than 2g/kg. The intravenous LD in these species is 50 to 60 mg/kg.

How should I store and handle Labetalol Hydrochloride?

Store below 30°C (86°F).Manufactured by:DANBURY PHARMACAL, INC.Danbury, CT 06810Store below 30°C (86°F).Manufactured by:DANBURY PHARMACAL, INC.Danbury, CT 06810LABETALOL HYDROCHLORIDE TABLETS, USP are available as follows:Labetalol hydrochloride tablets, 100 mg, beige, film coated, round, scored, debossed MP 277Bottles of 30 unit of use NDC 53489-354-07Bottles of 60 unit of use NDC 53489-354-06Bottles of 100 NDC 53489-354-01Bottles of 250 NDC 53489-354-03Bottles of 500 NDC 53489-354-05Bottles of 1000 NDC 53489-354-10Labetalol hydrochloride tablets, 200 mg, white, film coated, round, scored, debossed MP 271Bottles of 30 unit of use NDC 53489-355-07Bottles of 60 unit of use NDC 53489-355-06Bottles of 100 NDC 53489-355-01Bottles of 250 NDC 53489-355-03Bottles of 500 NDC 53489-355-05Bottles of 1000 NDC 53489-355-10Labetalol hydrochloride tablets, 300 mg, blue, film coated, round, unscored, debossed MP 272Bottles of 30 unit of use NDC 53489-356-07Bottles of 60 unit of use NDC 53489-356-06Bottles of 100 NDC 53489-356-01Bottles of 250 NDC 53489-356-03Bottles of 500 NDC 53489-356-05Bottles of 1000 NDC 53489-356-10LABETALOL HYDROCHLORIDE TABLETS, USP are available as follows:Labetalol hydrochloride tablets, 100 mg, beige, film coated, round, scored, debossed MP 277Bottles of 30 unit of use NDC 53489-354-07Bottles of 60 unit of use NDC 53489-354-06Bottles of 100 NDC 53489-354-01Bottles of 250 NDC 53489-354-03Bottles of 500 NDC 53489-354-05Bottles of 1000 NDC 53489-354-10Labetalol hydrochloride tablets, 200 mg, white, film coated, round, scored, debossed MP 271Bottles of 30 unit of use NDC 53489-355-07Bottles of 60 unit of use NDC 53489-355-06Bottles of 100 NDC 53489-355-01Bottles of 250 NDC 53489-355-03Bottles of 500 NDC 53489-355-05Bottles of 1000 NDC 53489-355-10Labetalol hydrochloride tablets, 300 mg, blue, film coated, round, unscored, debossed MP 272Bottles of 30 unit of use NDC 53489-356-07Bottles of 60 unit of use NDC 53489-356-06Bottles of 100 NDC 53489-356-01Bottles of 250 NDC 53489-356-03Bottles of 500 NDC 53489-356-05Bottles of 1000 NDC 53489-356-10LABETALOL HYDROCHLORIDE TABLETS, USP are available as follows:Labetalol hydrochloride tablets, 100 mg, beige, film coated, round, scored, debossed MP 277Bottles of 30 unit of use NDC 53489-354-07Bottles of 60 unit of use NDC 53489-354-06Bottles of 100 NDC 53489-354-01Bottles of 250 NDC 53489-354-03Bottles of 500 NDC 53489-354-05Bottles of 1000 NDC 53489-354-10Labetalol hydrochloride tablets, 200 mg, white, film coated, round, scored, debossed MP 271Bottles of 30 unit of use NDC 53489-355-07Bottles of 60 unit of use NDC 53489-355-06Bottles of 100 NDC 53489-355-01Bottles of 250 NDC 53489-355-03Bottles of 500 NDC 53489-355-05Bottles of 1000 NDC 53489-355-10Labetalol hydrochloride tablets, 300 mg, blue, film coated, round, unscored, debossed MP 272Bottles of 30 unit of use NDC 53489-356-07Bottles of 60 unit of use NDC 53489-356-06Bottles of 100 NDC 53489-356-01Bottles of 250 NDC 53489-356-03Bottles of 500 NDC 53489-356-05Bottles of 1000 NDC 53489-356-10LABETALOL HYDROCHLORIDE TABLETS, USP are available as follows:Labetalol hydrochloride tablets, 100 mg, beige, film coated, round, scored, debossed MP 277Bottles of 30 unit of use NDC 53489-354-07Bottles of 60 unit of use NDC 53489-354-06Bottles of 100 NDC 53489-354-01Bottles of 250 NDC 53489-354-03Bottles of 500 NDC 53489-354-05Bottles of 1000 NDC 53489-354-10Labetalol hydrochloride tablets, 200 mg, white, film coated, round, scored, debossed MP 271Bottles of 30 unit of use NDC 53489-355-07Bottles of 60 unit of use NDC 53489-355-06Bottles of 100 NDC 53489-355-01Bottles of 250 NDC 53489-355-03Bottles of 500 NDC 53489-355-05Bottles of 1000 NDC 53489-355-10Labetalol hydrochloride tablets, 300 mg, blue, film coated, round, unscored, debossed MP 272Bottles of 30 unit of use NDC 53489-356-07Bottles of 60 unit of use NDC 53489-356-06Bottles of 100 NDC 53489-356-01Bottles of 250 NDC 53489-356-03Bottles of 500 NDC 53489-356-05Bottles of 1000 NDC 53489-356-10LABETALOL HYDROCHLORIDE TABLETS, USP are available as follows:Labetalol hydrochloride tablets, 100 mg, beige, film coated, round, scored, debossed MP 277Bottles of 30 unit of use NDC 53489-354-07Bottles of 60 unit of use NDC 53489-354-06Bottles of 100 NDC 53489-354-01Bottles of 250 NDC 53489-354-03Bottles of 500 NDC 53489-354-05Bottles of 1000 NDC 53489-354-10Labetalol hydrochloride tablets, 200 mg, white, film coated, round, scored, debossed MP 271Bottles of 30 unit of use NDC 53489-355-07Bottles of 60 unit of use NDC 53489-355-06Bottles of 100 NDC 53489-355-01Bottles of 250 NDC 53489-355-03Bottles of 500 NDC 53489-355-05Bottles of 1000 NDC 53489-355-10Labetalol hydrochloride tablets, 300 mg, blue, film coated, round, unscored, debossed MP 272Bottles of 30 unit of use NDC 53489-356-07Bottles of 60 unit of use NDC 53489-356-06Bottles of 100 NDC 53489-356-01Bottles of 250 NDC 53489-356-03Bottles of 500 NDC 53489-356-05Bottles of 1000 NDC 53489-356-10LABETALOL HYDROCHLORIDE TABLETS, USP are available as follows:Labetalol hydrochloride tablets, 100 mg, beige, film coated, round, scored, debossed MP 277Bottles of 30 unit of use NDC 53489-354-07Bottles of 60 unit of use NDC 53489-354-06Bottles of 100 NDC 53489-354-01Bottles of 250 NDC 53489-354-03Bottles of 500 NDC 53489-354-05Bottles of 1000 NDC 53489-354-10Labetalol hydrochloride tablets, 200 mg, white, film coated, round, scored, debossed MP 271Bottles of 30 unit of use NDC 53489-355-07Bottles of 60 unit of use NDC 53489-355-06Bottles of 100 NDC 53489-355-01Bottles of 250 NDC 53489-355-03Bottles of 500 NDC 53489-355-05Bottles of 1000 NDC 53489-355-10Labetalol hydrochloride tablets, 300 mg, blue, film coated, round, unscored, debossed MP 272Bottles of 30 unit of use NDC 53489-356-07Bottles of 60 unit of use NDC 53489-356-06Bottles of 100 NDC 53489-356-01Bottles of 250 NDC 53489-356-03Bottles of 500 NDC 53489-356-05Bottles of 1000 NDC 53489-356-10LABETALOL HYDROCHLORIDE TABLETS, USP are available as follows:Labetalol hydrochloride tablets, 100 mg, beige, film coated, round, scored, debossed MP 277Bottles of 30 unit of use NDC 53489-354-07Bottles of 60 unit of use NDC 53489-354-06Bottles of 100 NDC 53489-354-01Bottles of 250 NDC 53489-354-03Bottles of 500 NDC 53489-354-05Bottles of 1000 NDC 53489-354-10Labetalol hydrochloride tablets, 200 mg, white, film coated, round, scored, debossed MP 271Bottles of 30 unit of use NDC 53489-355-07Bottles of 60 unit of use NDC 53489-355-06Bottles of 100 NDC 53489-355-01Bottles of 250 NDC 53489-355-03Bottles of 500 NDC 53489-355-05Bottles of 1000 NDC 53489-355-10Labetalol hydrochloride tablets, 300 mg, blue, film coated, round, unscored, debossed MP 272Bottles of 30 unit of use NDC 53489-356-07Bottles of 60 unit of use NDC 53489-356-06Bottles of 100 NDC 53489-356-01Bottles of 250 NDC 53489-356-03Bottles of 500 NDC 53489-356-05Bottles of 1000 NDC 53489-356-10

×

Clinical Information

Chemical Structure

No Image found

Clinical Pharmacology

The capacity of labetalol to block alpha receptors in man has been demonstrated by attenuation of the pressor effect of phenylephrine and by a significant reduction of the pressor response caused by immersing the hand in ice-cold water ("cold-pressor test"). Labetalol's beta-receptor blockade in man was demonstrated by a small decrease in the resting heart rate, attenuation of tachycardia produced by isoproterenol or exercise, and by attenuation of the reflex tachycardia to the hypotension produced by amyl nitrite. Beta-receptor blockade was demonstrated by inhibition of the isoproterenol-induced fall in diastolic blood pressure. Both the alpha- and beta-blocking actions of orally administered labetalol contribute to a decrease in blood pressure in hypertensive patients. Labetalol consistently, in dose-related fashion, blunted increases in exercise-induced blood pressure and heart rate, and in their double product. The pulmonary circulation during exercise was not affected by labetalol dosing.

Single oral doses of labetalol administered in patients with coronary artery disease had no significant effect on sinus rate, intraventricular conduction, or QRS duration. The AV conduction time was modestly prolonged in 2 of 7 patients. In another study, intravenous labetalol HCl slightly prolonged AV nodal conduction time and atrial effective refractory period with only small changes in heart rate. The effects on AV nodal refractoriness were inconsistent.

Labetalol produces dose-related falls in blood pressure without reflex tachycardia and without significant reduction in heart rate, presumably through a mixture of its alpha-blocking and beta-blocking effects. Hemodynamic effects are variable with small non-significant changes in cardiac output seen in some studies but not others, and small decreases in total peripheral resistance. Elevated plasma renins are reduced.

Doses of labetalol that controlled hypertension did not affect renal function in mild to severe hypertensive patients with normal renal function.

Due to the alpha-receptor blocking activity of labetalol, blood pressure is lowered more in the standing than in the supine position, and symptoms of postural hypotension (2%), including rare instances of syncope, can occur. Following oral administration, when postural hypotension has occurred, it has been transient and is uncommon when the recommended starting dose and titration increments are closely followed (see ). Symptomatic postural hypotension is most likely to occur 2 to 4 hours after a dose, especially following the use of large initial doses or upon large changes in dose.

The peak effects of single oral doses of labetalol occur within 2 to 4 hours. The duration of effect depends upon dose, lasting at least 8 hours following single oral doses of 100 mg and more than 12 hours following single oral doses of 300 mg. The maximum, steady-state blood pressure response upon oral, twice-a-day dosing occurs within 24 to 72 hours.

The antihypertensive effect of labetalol has a linear correlation with the logarithm of labetalol plasma concentration, and there is also a linear correlation between the reduction in exercise-induced tachycardia occurring at 2 hours after oral administration of labetalol and the logarithm of the plasma concentration.

About 70% of the maximum beta-blocking effect is present for 5 hours after the administration of a single oral dose of 400 mg, with suggestion that about 40% remains at 8 hours.

The anti-anginal efficacy of labetalol has not been studied. In 37 patients with hypertension and coronary artery disease, labetalol did not increase the incidence or severity of angina attacks.

Exacerbation of angina and, in some cases, myocardial infarction and ventricular dysrhythmias have been reported after abrupt discontinuation of therapy with beta-adrenergic blocking agents in patients with coronary artery disease. Abrupt withdrawal of these agents in patients without coronary artery disease has resulted in transient symptoms, including tremulousness, sweating, palpitation, headache, and malaise. Several mechanisms have been proposed to explain these phenomena, among them increased sensitivity to catecholamines because of increased numbers of beta receptors.

Although beta-adrenergic receptor blockade is useful in the treatment of angina and hypertension, there are also situations in which sympathetic stimulation is vital. For example, in patients with severely damaged hearts, adequate ventricular function may depend on sympathetic drive. Beta-adrenergic blockade may worsen AV block by preventing the necessary facilitating effects of sympathetic activity on conduction. Beta-adrenergic blockade results in passive bronchial constriction by interfering with endogenous adrenergic bronchodilator activity in patients subject to bronchospasm and may also interfere with exogenous bronchodilators in such patients.

Non-Clinical Toxicology

Labetalol tablets are contraindicated in bronchial asthma, overt cardiac failure, greater than first degree heart block, cardiogenic shock, severe bradycardia, other conditions associated with severe and prolonged hypotension, and in patients with a history of hypersensitivity to any component of the product (see ).

Beta-blockers, even those with apparent cardioselectivity, should not be used in patients with a history of obstructive airway disease, including asthma.

In one survey, 2.3% of patients taking labetalol in combination with tricyclic antidepressants experienced tremor as compared to 0.7% reported to occur with labetalol alone. The contribution of each of the treatments to this adverse reaction is unknown but the possibility of a drug interaction cannot be excluded.

Drugs possessing beta-blocking properties can blunt the bronchodilator effect of beta-receptor agonist drugs in patients with bronchospasm; therefore, doses greater than the normal anti-asthmatic dose of beta-agonist bronchodilator drugs may be required.

Cimetidine has been shown to increase the bioavailability of labetalol. Since this could be explained either by enhanced absorption or by an alteration of hepatic metabolism of labetalol, special care should be used in establishing the dose required for blood pressure control in such patients.

Synergism has been shown between halothane anesthesia and intravenously administered labetalol. During controlled hypotensive anesthesia using labetalol in association with halothane, high concentrations (3% or above) of halothane should not be used because the degree of hypotension will be increased and because of the possibility of a large reduction in cardiac output and an increase in central venous pressure. The anesthesiologist should be informed when a patient is receiving labetalol.

Labetalol blunts the reflex tachycardia produced by nitroglycerin without preventing its hypotensive effect. If labetalol is used with nitroglycerin in patients with angina pectoris, additional antihypertensive effects may occur.

Care should be taken if labetalol is used concomitantly with calcium channel antagonists of the verapamil type.

Most adverse effects are mild, transient and occur early in the course of treatment. In controlled clinical trials of 3 to 4 months duration, discontinuation of labetalol tablets due to one or more adverse effects was required in 7% of all patients. In these same trials, beta-blocker control agents led to discontinuation in 8% to 10% of patients, and a centrally acting alpha-agonist in 30% of patients.

The incidence rates of adverse reactions listed in the following table were derived from multicenter controlled clinical trials, comparing labetalol, placebo, metoprolol, and propranolol, over treatment periods of 3 and 4 months. Where the frequency of adverse effects for labetalol and placebo is similar, causal relationship is uncertain. The rates are based on adverse reactions considered probably drug related by the investigator. If all reports are considered, the rates are somewhat higher (e.g., dizziness 20%, nausea 14%, fatigue 11%), but the overall conclusions are unchanged.

The adverse effects were reported spontaneously and are representative of the incidence of adverse effects that may be observed in a properly selected hypertensive patient population, i.e., a group excluding patients with bronchospastic disease, overt congestive heart failure, or other contraindications to beta-blocker therapy.

Clinical trials also included studies utilizing daily doses up to 2400 mg in more severely hypertensive patients. Certain of the side effects increased with increasing dose as shown in the table below which depicts the entire U.S. therapeutic trials data base for adverse reactions that are clearly or possibly drug related.

In addition, a number of other less common adverse events have been reported:

Body As A Whole:

Cardiovascular:

Central and Peripheral Nervous Systems:

Collagen Disorders:

Eyes:

Immunological System:

Liver and Biliary System:

Musculoskeletal System:

Respiratory System:

Skin and Appendages:

Urinary System:

Hypersensitivity:

Following approval for marketing in the United Kingdom, a monitored release survey involving approximately 6,800 patients was conducted for further safety and efficacy evaluation of this product. Results of this survey indicate that the type, severity, and incidence of adverse effects were comparable to those cited above.

×

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

×

Review

×

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72

×

Tips

×

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).

Disclaimer: